How Testosterone Enanthate Affects hs-CRP

Hepatic CRP synthesis is IL-6 driven, so anything that shifts IL-6 production up or down moves hs-CRP with it. Testosterone has effects in both directions depending on dose, baseline inflammation, and body composition.

1. Anti-inflammatory at replacement doses in hypogonadal men: Restoring testosterone from clinically low to normal is associated with modest reductions in hs-CRP in some trials, driven partly by improvements in visceral adipose tissue and insulin sensitivity. The effect is small and inconsistent across trials.

2. Pro-inflammatory at supraphysiological doses: Chronic AAS users show elevated systemic inflammation independent of body composition. Grace and Davies (2004, PMID 14751958) documented CRP in AAS-using bodybuilders roughly 3-4 times higher than drug-free bodybuilders or sedentary controls. Rasmussen and colleagues have replicated the elevated inflammatory tone in multiple cohorts.

3. Direct AR-mediated signalling: Androgen receptor activation in vascular and immune cells modulates cytokine production. At supraphysiological doses this signalling can drive pro-inflammatory pathways.

4. Endothelial stress from erythrocytosis: Rising haematocrit increases blood viscosity and endothelial shear stress, which drives low-grade inflammation independent of the direct androgen signal. This is one mechanism by which polycythaemia (Ory 2022, PMID 35050717) links to MACE and VTE.

5. 17-alpha-alkylated orals amplify the signal: Oral compounds add hepatic stress on top of the AR signal, further raising hs-CRP.

Replacement doses (100-200 mg/week, on-treatment total T inside reference range):

• hs-CRP typically unchanged or modestly lower over 12-24 weeks
• Effect is largest in men who were both hypogonadal and carrying visceral fat at baseline
• Some trials show no change at all

Cruise doses (200-300 mg/week, on-treatment total T above reference range):

• hs-CRP begins drifting upward
• Baseline of 1.0 mg/L can rise to 1.5-2.5 mg/L over 12 weeks
• The rise is larger with concurrent oral compounds

Blast doses (500+ mg/week) or oral stacks:

• hs-CRP commonly runs 2-4 mg/L on cycle
• Chronic long-term AAS users show sustained elevations of 3-4 times drug-free lifter baseline (Grace and Davies 2004)

Post-cycle:

• hs-CRP typically returns toward baseline within 8-12 weeks of cessation
• Chronic long-term users show partial reversibility only, with residual elevation reflecting persistent vascular inflammation

Baseline: fasting hs-CRP before starting or before adding a new compound. Draw at least 5 days clear of anything heavy or novel in training, and at the same lab and time of day for repeat draws.

Two readings, not one: within-subject coefficient of variation for hs-CRP is roughly 41-44%. A single reading does not represent basal level. Two readings at least 2 weeks apart, both in the absence of acute illness, is the AHA convention.

Discard readings above 10 mg/L: those represent acute inflammation (recent infection, injury, hard training session) rather than vascular risk. Retest.

On cycle: recheck at week 8 and week 12. If hs-CRP has climbed above 2 mg/L and you cannot attribute it to a training session or infection, the drug or the dose is the likely driver.

Target on cycle: under 1 mg/L is the low-CV-risk threshold. On cycle, staying under 2 mg/L is a reasonable practical target for most users. Sustained hs-CRP above 3 mg/L warrants investigation.

Fix the drivers before crediting the drug: hard training sessions, poor sleep, chronic under-eating relative to training load, and hidden infection all elevate hs-CRP. Rule those out before attributing an elevation to the compound.

Move to injectable-only if possible: oral 17-alpha-alkylated compounds add hepatic stress that lifts hs-CRP independently. Removing the oral often drops hs-CRP by 30-50%.

Rosuvastatin 5-10 mg per day drops hs-CRP by roughly 30-40% independent of LDL effect (JUPITER trial). This is the pharmacological option most cited for AAS users with concurrent lipid derangement.

Omega-3 (2-3 g EPA/DHA per day) modestly reduces hs-CRP and is a reasonable adjunct.

If hs-CRP stays above 3 mg/L off cycle, the residual inflammation is the flag for further workup. Consider hidden infection, dental health, autoimmune activity, and persistent vascular inflammation from long-term AAS use.

Further reading: TRT does not cause heart attacks, but blasting is different. On-cycle support protocol, every supplement mapped to your bloodwork.